U.S. FDA Grants Accelerated Approval To Bristol Myers Squibb's First Celmod Therapy Zenbexus™, In Combination With Daratumumab And Hyaluronidase-Fihj And Dexamethasone (Zdd) For Patients With Multiple Myeloma, As Early As First Relapse - BMY News | Rallies
U.S. FDA Grants Accelerated Approval To Bristol Myers Squibb's First Celmod Therapy Zenbexus™, In Combination With Daratumumab And Hyaluronidase-Fihj And Dexamethasone (Zdd) For Patients With Multiple Myeloma, As Early As First Relapse
U.S. FDA grants accelerated approval to Bristol Myers Squibb's first celmod therapy Zenbexus™, in combination with daratumumab and hyaluronidase-fihj and dexamethasone (Zdd) for patients with multiple myeloma, as early as first relapse.
Bristol-Myers Squibb said Zenbexus is available only through restricted Zenbexus REMS program.
BMY•
